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ABSTRACT
Improving understanding of the underlying
pathophysiology of giant cell arteritis (GCA) is
transforming clinical management by identify-
ing novel avenues for targeted therapies. One
key area of concern for both clinicians and
patients with GCA is glucocorticoid (GC) mor-
bidity. The first randomised controlled trials of
targeted treatment to reduce cumulative GC use
in GCA have been published, with tocilizumab,
an interleukin (IL)-6 receptor inhibitor, now the
first ever licensed treatment for GCA. Further
potential therapies are emerging owing to our
enhanced understanding of the pathophysiol-
ogy of the disease. Other improvements in the
care of our patients are rapid access pathways
and imaging techniques, such as ultrasound,
which are becoming part of modern rheuma-
tology practice in the UK, Europe and beyond.
These have been highlighted in the literature to
reduce delay in diagnosis and improve long-
term outcomes for those investigated for GCA.
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INTRODUCTION
Giant cell arteritis (GCA) is an idiopathic gran-
ulomatous vasculitis primarily involving med-
ium- and large-calibre branches of the aorta [1].
It is the most common vasculitis in those of
Caucasian ancestry aged above 50 years and
exhibits a female preponderance [2–4]. This
often-elusive condition if left untreated can lead
to sight-threatening complications [5]. The
mainstay of therapy in GCA has long been
glucocorticoids (GC), which in themselves
confer significant morbidity [6]. It is
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increasingly recognised that although GCA is
traditionally seen as a GC-responsive disease,
therapy typically lasts between 18 and
24 months with all requiring high dose therapy
initially and some requiring long-term therapy,
and when studied in the context of clinical tri-
als only 15–20% of patients achieve long-term
remission [7], highlighting the need for alter-
native therapies [8]. This review article is based
on previously conducted studies and will pre-
sent the recent advances in the diagnostic and
therapeutic armamentarium in GCA. This arti-
cle is based on previously conducted studies and
does not contain any studies with human par-




The lifetime risk of developing GCA is 1% for
women and 0.5% for men [9] with a reported
worldwide incidence ranging between 1 in
100,000 and 30 in 100,000 [10]. This appears to
be related to a number of factors, including age,
latitude, genetic susceptibility and ethnic
background [9–22]. Amongst these well-estab-
lished risk factors, age is widely regarded as the
most significant. In a cross-sectional study
conducted in northern Spain, a near 20-fold
increase in the incidence of GCA was reported
between those in their 6th decade of life as
compared to those in their 9th decade. Similar
trends have also been reported by studies con-
ducted in the UK [12], Scandinavia [13, 14],
Italy [15, 16] and the USA [17–20].
GCA most commonly affects those of
northern European and Scandinavian descent
[21]. This in part seems to be attributable to
genetic factors; of particular interest have been
the major histocompatibility complex (MHC)
genes [22–26]. Most recently, a large genome-
wide association study in GCA was conducted
on 1651 cases and 15,306 controls from six
countries of European ancestry [24]. This
revealed the human leucocyte antigen (HLA)
class II gene loci as those with the strongest
association to GCA susceptibility and specifi-
cally highlighted DRB1*04, DQA1*03 and
DQB1*03 alleles as those contributing most
significantly to this signal. This data builds on
the previous body of evidence describing a
strong association between HLA-DRB1*04 car-
rier status and an increased risk of GCA [25].
Interestingly, a higher population frequency of
the HLA-DRB1*04 allele has been reported in
more northerly latitudes [26], providing insight
into the potential determinants of the geo-
graphic variability of GCA incidence.
MHC class I genes have also been implicated
as risk factors in GCA, with a strong association
being described between the propensity for
GCA and the HLA-B gene locus [24, 26, 27].
Further, genotype interrogation of the MHC
class I chain-related gene A (MICA), which
encodes putative stress-inducible heat shock
elements [26], has been shown to confer sus-
ceptibility to GCA in a northern Spanish cohort
[27]. This appeared to be independent of linkage
disequilibrium with HLA-B and exhibited a
cumulative risk effect when concurrent with the
HLA-B15 haplotype or the HLA-DRB1*04 allele
[27].
Of the non-MHC genes found to predispose
to GCA, the strongest evidence is in support of
the interleukin-12b (IL-12b) gene [22]. Geno-
typing by immunochip array performed on a
cohort compromising of 997 Spanish and Ital-
ian cases and 2775 controls reported the largest
signal outside the MHC region to be the single
nucleotide polymorphism (SNP) rs755374 in
the IL-12b gene locus [23]. This relationship was
confirmed in a further four cohorts of European
ancestry. Remarkably, this gene is traditionally
associated with an increased risk of Takayasu’s
arteritis [23]. Other non-MHC genes, such as
TNF-a microsatellite [28] and interleukin-6 (IL-
6) [29], appear to be of emerging significance.
However, better powered studies of more
diverse populations are needed to validate their
importance as risk genes.
IMMUNOPATHOBIOLOGY
GCA is a T cell driven disease characterised by
the formation of vessel wall granulomas, inti-
mal hyperplasia and end-organ ischaemia
[21, 30]. It is a disease of immune dysregulation
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and, as such, emerging data not only sheds light
on the importance of Th1 and Th17 pathways
but also on the role of innate immunity in
propagating and sustaining the inflammatory
milieu (Fig. 1) [30–35].
Vascular Dendritic Cells
In health, immature vascular dendritic cells
(DCs) positioned at the adventitial–medial
interface migrate to lymphoid organs if acti-
vated, thus preserving the immune-privileged
status of the vessel wall [36]. In GCA however,
DCs undergo activation and maturation within
the arterial vessel wall and remain in situ
[37, 38]. They express surface molecules and
chemokines which recruit and activate local
innate immune cells, such as monocytes and
fibroblasts, whilst also crucially gaining the
ability to activate naı¨ve CD4? T cells [38–40]. It
is as yet unclear what triggers this breach in
tolerance and though some have postulated a
role for infectious agents [41–43], the literature
remains contradictory [44, 45].
Macrophages
Macrophages are known to secrete matrix met-
alloproteinases, which degrade the internal
elastic lamina and smooth muscle cells within
the media, promoting the migration and prolif-
eration of myofibroblasts into and within the
intima [10, 46]. This produces a classically
hyperplastic intima leading to luminal compro-
mise. Importantly, macrophages release IL-6 and
IL-1b, potent cytokines required for the differ-
entiation of Th17 effector cells [36, 37, 46, 47].
Interestingly, the circulating levels of IL-6 have
Fig. 1 Flow diagram on the key immunopathophysiology of GCA
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been found to correlate with the severity of the
acute inflammatory response in GCA and fluc-
tuate in line with disease activity [32]. However,
higher levels of IL-6 also appear to confer a lower
risk of ischaemic complications, a puzzling
conundrum thought to be related to the pro-an-
giogenic effects of IL-6 [33, 48, 49].
Th1 and Th17
Two main lineages of CD4? T cells are involved
in the pathogenic inflammatory response which
drives GCA. Th1 cells differentiate in the pres-
ence of IL-12, thought to be produced by acti-
vated vasDCs [32]. These effector T cells are
responsible for the secretion of interferon-c
(IFN-c), a potent activator of macrophages and
heavily implicated in promoting mural infiltra-
tion, as well as giant cell and granuloma for-
mation [35, 50, 51]. Th17 cells on the other
hand are reliant on IL-6 and IL-1b from mac-
rophages to differentiate. They are characterised
by the production of IL-17 but also secrete IL-
23, GM-CSF and IL-22 among others [35, 52].
These cytokines are implicated in recruiting
innate immune cells, propagating local mes-
enchymal cell proliferation and activation of
hepatocytes to secrete acute phase proteins [32].
In contrast to IL-6 and IL-17, which appear
to wax and wane with disease activity and are
highly responsive to GC, elevated levels of IL-12
and IFN-c persist within the serum of patients
and within temporal artery samples despite
months of GC treatment [33]. Moreover, higher
levels of IL-12 and IFN-c correlate with a greater
burden of ischaemic complications [33, 52].
These findings lend credence to the idea of a
phasic inflammatory process, where the Th17
(IL-6/IL-17)-mediated pathway, which is GC
responsive, drives inflammation in early GCA,
while Th1 (IL-12/IFN-c)-mediated mechanisms
promote chronicity and are poorly GC respon-
sive [30–33]. This further explains the histo-
logical findings of a sustained vasculitis and the
development of aortic aneurysms long after the
commencement of GC therapy [33] and, most
importantly of all, the suboptimal numbers of
patients that actually achieve long-term remis-
sion despite GC therapy [7].
CLINICAL PRESENTATION
Giant cell arteritis is renowned for its insidious
onset, heterogenous presenting features and
constitutional symptoms, which often con-
tribute to diagnostic uncertainty and delay in
treatment [34]. Up to 40% of patients present
atypically [53] and the pattern of disease
involvement ranges from cranial involvement
such as anterior ischaemic optic neuropathy
(Fig. 2), retinal arterial occlusions (Fig. 2) and
choroidal infarction (Fig. 3) to extracranial such
as symptoms of polymyalgia rheumatica or
large vessel vasculitis (Table 1); they can be
mutually exclusive or a combination of the
spectrum. This condition can therefore present
to many specialists which can further com-
pound a diagnostic delay [34]. Many studies
have examined the presenting features, and
among those with the highest positive predic-
tive value include scalp tenderness and/or jaw
claudication (Fig. 4) [54, 55]. The natural his-
tory of the disease varies, and because of the
advent of targeted treatment disease stratifica-
tion is required, with clear definitions of disease
states (Table 2) [8].
SECURING A DIAGNOSIS OF GCA
Securing a diagnosis of GCA can be challenging,
and requires a prompt, thorough history, full
clinical examination and a combination of
investigations. Laboratory findings in GCA
typically reflect a pro-inflammatory picture
with a prolonged ESR, increased plasma viscos-
ity, raised CRP, thrombocytosis, raised alkaline
phosphatase and a normochromic normocytic
anaemia [56]. CRP is the most sensitive indi-
vidual serological marker [57] and should
always be checked. An isolated raised ESR with
normal CRP should prompt a search for alter-
native diagnoses (e.g. myeloma, connective tis-
sue disease).
Given that the standard treatment confers
significant risk of morbidity most agree that a
confirmatory investigational test is required.
Temporal artery biopsy (TAB) allows for a his-
tological diagnosis, abrogates diagnostic doubt
and provides justification for the use of
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Fig. 2 An 85-year-old woman presented with bilateral
visual loss. Right visual acuity 6/18, left perception of light.
Erythrocyte sedimentation rate (ESR) 88 mm/h and
C-reactive protein (CRP) 66 (normal range less than 5).
Temporal artery ultrasound scan positive halos bilaterally.
Colour images show bilateral cilioretinal artery occlusions
and left arteritic anterior ischaemic optic neuropathy
Fig. 3 An 82-year-old man with transient visual distur-
bance of the right eye, right temporal tenderness and jaw
claudication. ESR 66 mm/h. Cotton wool spots along
superotemporal and inferotemporal retinal vascular
arcades. Fluorescein angiography sequence showed chor-
oidal ischaemia in these areas. Temporal artery biopsy was
positive
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prolonged courses of GC and the morbidity
which accompanies their use. Histologically,
the inflammatory infiltrate in GCA is
Fig. 4 Clinical factors predicting a positive temporal
artery biopsy in order of magnitude. Adapted from
Gonza´lez-Lo´pez et al. [55]
Table 2 Deﬁnitions of disease activity in GCA. Adapted
from Coath et al. [8]
Terminology Deﬁnition
Relapse Recurrence of signs or symptoms of GCA
attributable to GCA as determined by
the healthcare professional necessitating
an increase in treatment in a GCA
patient who has previously responded to
treatment
Refractory People with GCA who never achieve
remission, regardless of treatment with a
course of glucocorticoids, which would
be considered adequate in others to
induce remission. Lower dose regimens
may constitute optimal care if the
maximum safe dose of glucocorticoid
must be exceeded in order to control
disease e.g. in glucocorticoid-induced
psychiatric disturbance, pancreatitis, or
uncontrolled diabetes or hypertension
Remission Absence of signs or symptoms of GCA.



















Transient monocular visual loss
(amaurosis fugax)
Permanent loss of vision
Anterior ischaemic optic
neuropathy (Fig. 2)
Central retinal artery occlusion
(Fig. 2)
Branch retinal artery occlusion
Posterior ischaemic optic
neuropathy
Choroidal infarction (Fig. 3)
Transient diplopia
Persistent diplopia











predominantly composed of histio-
cytes/macrophages and CD4-positive lympho-
cytes, with variable involvement of the three
arterial layers (Fig. 5), often showing only seg-
mental/sectorial inflammation in parts of the
arterial wall. The lymphocyte population usu-
ally includes lesser numbers of CD8? cytotoxic
lymphocytes and even small clusters of CD20?
B lymphocytes (Fig. 6). Focal fusion of histio-
cytes and formation of multinucleate giant cells
are seen (Fig. 7), but these are not required for
the diagnosis. Morphologically, four different
inflammatory patterns can be differentiated
with the panarteritic pattern being the most
common (69%), followed by the concentric
bilayer pattern (18%) (Fig. 6) with involvement
of intima and adventitia, and least common,
two adventitial patterns, with and without local
invasion of the media (7% and 6%, respectively)
[58]. The inflammation typically results in
breaks, segmental loss and reduplication of the
elastic lamina. This is best seen on elastin stain
that highlights disruption, segmental discon-
tinuation and focal reduplication of elastica
(Fig. 8). This may cause critical luminal nar-
rowing and aneurysm formation. When the
active phase of the disease has vanished,
inflammatory cell infiltrates may be absent but
Fig. 5 Active GCA. a Transverse arterial proﬁle demon-
strating segmental chronic inﬂammation and thickening of
intima and circumferential chronic inﬂammation of
adventitia (patchy concentric bilayer pattern), HE 940
magniﬁcation. b Close-up of a; partial transverse arterial
proﬁle revealing granulomatous lymphohistiocytic
inﬂammation in intima and predominantly lymphocytic
inﬂammation in adventitia, HE 9100 magniﬁcation. C
Close-up of a/b; partial transverse arterial proﬁle showing
granulomatous lymphohistiocytic inﬂammation in intima
and discontinuous elastic lamina, HE 9200 magniﬁcation
Fig. 6 The case illustrated matches most closely the
concentric bilayer pattern, although the media is also
focally inﬂamed, overlapping with the panarteritic pattern.
The cellular composition is dominated by histio-
cytes/macrophages in the intima and T lymphocytes in
the adventitia, with CD4? lymphocytes being the com-
monest subtype (a), lesser numbers of CD8? lymphocytes
(b) and a few CD20? lymphocytes (c). Large multinu-
cleate giant cells are not seen; however, occasional
binucleate macrophages are noted. The elastic lamina
displays breaks and patchy discontinuation, as well as focal
reduplication
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intimal-medial scarring and injury to the elastic
lamina often remains, allowing a diagnosis of
‘healed arteritis’. A recent report links the
CD68? (cluster of differentiation 68?) macro-
phage marker in TABs with those who are
refractory to initial GC tapers, and those even-
tually placed on immunomodulatory therapy
[59].
The sensitivity of TAB can vary between 39%
and 91% because of skip lesions, inadequate
sample length and the initiation of GC prior to
biopsy [60, 61]. The resultant high false nega-
tive rate could potentially lead to patients being
continued on GC as a precautionary measure.
The true false negative rate of TAB cannot be
estimated with certainty as the clinical diagno-
sis of TAB-negative, TAUS-negative GCA cannot
be confirmed diagnostically. Consequently, the
European League Against Rheumatism (EULAR)
recommendations on the diagnosis of large
vessel vasculitis have been updated to include
the use of non-invasive imaging techniques to
assist or even supersede TAB in certain circum-
stances [62]. The first study examining the
diagnostic application of ultrasound (USS) in
GCA was conducted in 1997 by Schmidt et al.
[63]. They assessed 30 patients for the presence
of:
1. Halo sign – analogous to oedema of the
temporal artery wall (Fig. 9)
2. Stenosis and
3. Occlusion of the temporal artery
They found the halo sign to have a sensitivity of
73% and specificity of 100% when compared
with the final diagnosis. Three meta-analyses
have provided an evidence base for the role of
USS in the diagnosis of GCA [64–66]. Typically
reported sensitivities range between 68% and
Fig. 8 a Elastin stain highlights disruption, segmental
discontinuation and focal reduplication of elastica (black
lines), EvG 940 magniﬁcation. b Close-up of a;
disruption, segmental discontinuation and focal reduplica-
tion of elastica (black lines), EvG 9100 magniﬁcation
Fig. 7 a Partial transverse arterial proﬁle displaying gran-
ulomatous lymphohistiocytic inﬂammation in intima and
adventitia, with minor inﬂammatory changes in media, HE
9200 magniﬁcation. b Close-up of a; Intima with
granulomatous inﬂammation, showing focal fusion of
histiocytes, forming multinucleate giant cells, HE 9400
magniﬁcation. c Large multinucleate giant cell in intima,
HE 9400 magniﬁcation
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75% and specificities between 83% and 92%,
when either final histological or clinical diag-
nosis is used as the comparator gold standard. It
should be noted that the ability to detect a halo
sign declines rapidly after the initiation of glu-
cocorticosteroid (GC) with sensitivity falling to
below 50% at 4 days [64, 65, 66]. The specificity
of the halo sign is increased with the use of the
‘compression test’: a true halo will not disappear
if the probe is used to compress the temporal
artery [67].
The EULAR taskforce for imaging in large
vessel vasculitis guideline recommended USS as
the first-line imaging modality for predomi-
nantly cranial GCA in centres where experience
is at hand, as the test is less invasive and thus
well tolerated by elderly and often frail indi-
viduals, the result is not delayed and it is cost-
effective [62]. Experience of USS for GCA has led
to the reduction in numbers of TABs being
performed at some centres [68, 69]. Addition-
ally, USS of both the temporal artery and the
axillary artery increases the yield of the diag-
nosis [68].
For large vessel GCA, other imaging tech-
niques are emerging as clinically useful. 18F-flu-
orodeoxyglucose positron emission tomography
(18F-FDG-PET) is usually combined with low-
dose computed tomography (CT) assessing dis-
ease activity and extent of involvement [70].
Although large vessel imaging is sensitive to GC
therapy,uptake canpersist despite treatment and
absence of clinical symptoms in some. Research
areas in GCA imaging include super high-reso-
lution magnetic resonance imaging (MRI) of the
superficial and extracranial arteries demonstrat-
ing arterial wall thickening with peri-adventitial
and mural contrast enhancement [71] and
transdermal optical coherence tomography
(OCT) of the superficial temporal artery [72].
MANAGEMENT
Suspected GCA remains a medical emergency,
and the number of cases investigated for GCA is
rising [73]. Rapid access clinics, often with
access to TA USS and combined
Fig. 9 Temporal artery ultrasound images showing a longitudinal and b cross-sectional images of a normal artery; c
longitudinal and d cross-sectional image of the non-compressible, hypoechoic halo sign
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ophthalmology/rheumatology clinical exper-
tise, have been reported to improve patient
outcomes [62, 68]. It should be noted that ex-
cluding GCA as a diagnosis is also important to
prevent patients without disease being exposed
to prolonged GC exposure unnecessarily.
Glucocorticosteroids remain the gold-stan-
dard treatment in GCA; it is a consensus-based
approach rather than one supported by well-
powered prospective studies [56]. Short-term
side effects such as GC-induced psychosis can
be challenging to treat and long-term GC use is
associated with a multitude of adverse effects
including an increased susceptibility to infec-
tions, osteoporotic fractures, diabetes, hyper-
tension, glaucoma, gastric ulcer disease and
mood disorders, amongst others [74]. A recent
study by Proven et al. reported that 86% of
patients developed at least one GC-related
complication over a 10-year period [75]. These
worrying findings in the context of an aged
population with a high baseline burden of
comorbidities have prompted research into GC-
sparing agents in the form of traditional disease-
modifying antirheumatic drugs (DMARDs) and,
more recently, targeted biologic agents.
DMARDS
To date, only three randomised, placebo-con-
trolled trials have examined the efficacy of
methotrexate (MTX) as an adjunctive GC-spar-
ing agent and these have reported conflicting
results [76–78]. A meta-analysis of these studies
revealed that patients treated with MTX had a
significant, though modestly reduced risk of
relapse compared with placebo, and this on
lower cumulative GC doses [79]. Notably,
however, and despite the apparent GC-sparing
effect of MTX, there was no significant differ-
ence in the rate of drug-related adverse events
between the intervention and placebo-con-
trolled groups [79]. These studies were con-
ducted with low-dose MTX and in patients in
whom GC titration from low doses had failed
on several occasions, which may explain why
the results were marginal.
Leflunomide has been shown to be effective
in Takayasu’s arteritis and other T cell driven
diseases such as rheumatoid arthritis. In the few
retrospective case-series reported in the litera-
ture, statistically significant GC-sparing effects
have been witnessed though these equate to
minimal absolute reductions in cumulative GC
doses [80, 81]. A paucity of well-powered
prospective studies assessing leflunomide effi-
cacy in GCA means it does not yet appear to
have a role in GCA. However, a recent open-
label prospective study conducted by Hocˇevar
et al. [82] has shown some promise, supporting
the need for well-powered randomised con-
trolled trials (RCTs) to further interrogate the
role of this drug.
Other conventional DMARDs such as aza-
thioprine [83], cyclophosphamide [84] and
mycophenolate [85] have not been shown to be
superior to GC alone, whilst ciclosporin has
been deemed ineffective [86]. Other adjunctive
therapy, such as aspirin, has previously been




With the emergence of an apparently central
role for IL-6 in the pathogenesis of GCA, it is no
surprise that biologic agents that modulate this
cytokine and subsidiary molecules and recep-
tors have been of increasing interest in the
search for novel therapeutic agents. Tocilizu-
mab (TCZ), a humanised monoclonal antibody
to the IL-6 receptor, has shown exciting results
in phase II [88] and phase III trials [89]. Villiger
et al. [88] conducted the first RCT of TCZ in
GCA, where 30 patients with new-onset or
relapsing disease were randomised to receive
either weekly TCZ infusions or placebo, both
with a tapering GC regimen. At week 12, 85% of
the TCZ group had achieved clinical and bio-
chemical remission as compared with only 40%
of those in the placebo group (p = 0.03). Simi-
larly, at 1 year, 85% of the TCZ group had
remained relapse-free versus a mere 20% of the
placebo group (p = 0.001), all whilst conferring
a significant GC-sparing effect (in favour of
TCZ).
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Subsequently, the Giant Cell Arteritis
Actemra (GiACTA) trial was conducted by Stone
et al. [89]. This large phase III, multicentre,
double-blind, placebo-controlled study exam-
ined the efficacy of TCZ to induce and sustain
remission to 1 year [89]. A total of 119 patients
with newly diagnosed GCA and 132 patients
with refractory disease were enrolled and ran-
domised to one of four arms: weekly or fort-
nightly dosing of TCZ with a 26-week
prednisolone taper or placebo plus a 26-week or
52-week prednisolone taper. At 1 year, patients
in the TCZ groups were significantly more likely
to have achieved sustained remission as com-
pared with both the 26-week and 52-week GC
taper groups, and at just over half the cumula-
tive GC dose. However, despite the impressive
GC dose reduction over the course of the study,
there was no significant difference in the rate of
adverse events between the TCZ and placebo-
controlled groups. Villiger et al. [88] reported an
increased infection rate in the treated group and
this was not found in GiACTA [89]. Extrapolat-
ing safety data from rheumatoid arthritis must
be met with caution because of the significant
age difference between the two distinct disease
groups [90]. Of particular concern in the GCA
population are diverticular disease, transient
neutropenias, and elevations of triglycerides
and deranged liver function tests.
It should be noted that in GiACTA both
placebo arms had a significantly faster GC taper
than used in routine clinical practice and thus
the real-life GC-sparing effect may prove to be
less marked. Also 1/3 patients had diagnosis
based on large vessel imaging, which is cur-
rently not routine clinical practice. The 2-year
open-label outcomes for this trial are currently
anticipated. These results will shed light on the
long-term safety profile and efficacy of TCZ at
maintaining disease-free remission, and will
help elucidate the extent of its GC-sparing
effects including the potential for GC-free
remission.
Nonetheless, these trials have provided the
evidence-base for a paradigm shift with tocili-
zumab being the first ever drug licensed by the
Food and Drug Agency (FDA) and the European
Medicines Agency (EMA) for GCA [91].
TNF-a Blockade
Amongst its many pro-inflammatory functions,
TNF-a is a potent chemotactin and is known to
activate macrophages, T cells and local mes-
enchymal cells, thereby fuelling the inflamma-
tory milieu [35]. However, whilst monoclonal
antibodies antagonising the function of TNF-a
have become a fixture in the treatment of
autoimmune inflammatory conditions, the
results from phase II RCTs conducted in GCA
have been disappointing [92–94]. These find-
ings suggest that although TNF-a plays an
important role in the inflammatory response in
GCA there may be other circumventing pro-in-
flammatory pathways, which despite TNF-a
blockade, remain active.
IL-12/IL-23 Blockade
We have discussed the role of Th1 and Th17
pathways in the immunopathobiology of GCA,
Th17 being implicated in the early, GC-re-
sponsive inflammatory phase and Th1 in the
chronic, poorly GC-responsive phase of the
disease. IL-12 and IL-23 are key cytokines which
regulate T cell differentiation into Th1 and
Th17 effector cells, respectively [30–34]. Enter
ustekinumab, a monoclonal antibody to the
p40 subunit, common to both IL-12 and IL-23.
An open-label prospective study of ustek-
inumab in refractory GCA was performed by
Conway et al. [95]. Twenty-five patients with
refractory GCA were commenced on a weaning
course of prednisolone and subcutaneous
ustekinumab injections every 12 weeks. At
1 year, none of the participants had experienced
a relapse and 24% had achieved GC-free remis-
sion. Reductions in CRP levels and daily GC
doses were found to be significant. Though the
results of this study are not overwhelming, they
do provide insight into the potential therapeu-
tic capacity of ustekinumab in GCA. A similar
open-label study is currently recruiting, results
of which are expected in 2020 [96].
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T Cell Activation
Abatacept (CTLA4-Ig) is a recombinant fusion
protein which interferes with the CD28-medi-
ated co-stimulation required for T cell activa-
tion. Langford et al. [97] examined the efficacy
of abatacept in maintaining disease-free remis-
sion in patients with newly diagnosed or
relapsing GCA in a multicentre, double-blind
RCT. Forty-nine patients from 11 centres were
commenced on the trial receiving high-dose
prednisolone and four abatacept infusions over
the course of 8 weeks. By week 12, 41 patients
had achieved disease-free remission and were
randomised to either continue on monthly
abatacept or switch to placebo, both while
continuing on a weaning GC regime. The study
reported a minimally significant (p = 0.049)
increase in relapse-free survival in the abatacept
group at 1 year as well as a significant
(p = 0.023) increase in the duration of remission
in this group.
The authors comment that though the result
of this study showed low-level significance, they
felt this represented a clinically significant out-
come [97]. A notable and possible confounding
factor in the study design was that all partici-
pants received abatacept prior to randomisation
as a means to induce remission in conjunction
with high-dose GC. Though of course this
design may help to detect safety issues early on
in the trial, it may have inadvertently diluted
the effect size through a carry-over effect in
those subsequently randomised to the placebo
group. As ever, better powered RCTs are
required to further evaluate the efficacy of
abatacept in GCA.
IL-1b Receptor Blockade
IL-1b is a prerequisite cytokine for the differ-
entiation of Th17 cells, which appear to play a
central role in GCA [35]. Anakinra, a mono-
clonal antibody to the IL-1b receptor, is thus
thought to be of potential therapeutic benefit. A
small case series has been reported [98] and a
phase III trial is now planned to compare the
efficacy of anakinra as an adjunctive GC-sparing
drug in GCA [99]. Gevokizumab, a recombinant
monoclonal antibody to IL-1b, is currently
under investigation in a multicentre, double-
blind RCT [100].
Other Avenues
It as yet unclear what role, if any, humoral
immunity plays in the pathogenesis of GCA. It
has been postulated that given the integral role
of B cells in the T cell life cycle, B cell depletion
in the form of rituximab could be a potential
therapeutic avenue [46]. Case reports have
shown some benefit in select patient groups but
further study is required [101]. An intriguing
novel oral drug currently recruiting to phase II
trials is baricitinib, a synthetic DMARD which
targets the intracellular pro-inflammatory Janus
kinase (JAK) family of enzymes [102]. Results
from the GCA cohort are awaited.
CONCLUSIONS
Understanding of the immunopathophysiology
of GCA has now translated into the first
licensed targeted treatment for GCA, with an IL-
6 inhibitor, tocilizumab. This is the beginning
of addressing the unmet need in GCA of GC
toxicity and morbidity. The development and
routine availability of non-invasive imaging in
conjunction with clinical expertise is becoming
the gold standard for practice in GCA.
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